ABVC BIOPHARMA INC (ABVC)
US00091F3047 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 137.34K | 60.16K | 90.00K | 5.83M | 4.27M | |||
| Marketable Securities | 70.81K | 79.31K | 80.00K | 110.00K | N/A | |||
| Receivables | 1.22M | 759.57K | 1.37M | 1.71M | 1.00M | |||
| Inventories | N/A | N/A | 0.00 | 30.00K | 0.00 | |||
| Other Current Assets | 723.82K | 757.68K | 1.46M | 1.95M | 900.00K | |||
| Total Current Assets | 2.15M | 1.66M | 2.99M | 9.63M | 6.17M | |||
| Non-Current Assets | ||||||||
| PPE Net | 8.44M | 8.78M | 1.74M | 2.00M | 2.29M | |||
| Investments And Advances | 2.33M | 2.53M | 840.00K | 930.00K | 1.19M | |||
| Goodwill | N/A | N/A | N/A | 0.00 | N/A | |||
| Intangibles | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 1.42M | 1.42M | 3.15M | 1.14M | 1.96M | |||
| Total Non-Current Assets | 12.31M | 12.84M | 6.87M | 4.07M | 5.44M | |||
| TOTAL ASSETS | 14.46M | 14.49M | 9.86M | 13.70M | 11.61M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 866.25K | 899.25K | 1.89M | 1.64M | 1.84M | |||
| Current Portion Of LT Debt. | 952.24K | 569.46K | N/A | 0.00 | 250.00K | |||
| Accrued Expenses | 3.55M | 4.10M | 3.28M | 1.65M | 2.44M | |||
| Accounts Payable | N/A | N/A | N/A | 0.00 | 20.00K | |||
| Other Current Liabilities | 951.16K | 365.58K | 650.00K | 400.00K | 300.00K | |||
| Total Current Liabilities | 6.32M | 5.93M | 5.82M | 3.69M | 4.84M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 2.62M | |||
| Other Non-Current Liabilities | 167.88K | 429.14K | 800.00K | 1.14M | 1.48M | |||
| Total Non-Current Liabilities | -211.26K | 172.06K | 940.00K | 1.16M | 3.33M | |||
| TOTAL LIABILITIES | 6.10M | 6.10M | 6.76M | 4.85M | 8.17M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -70.55M | -65.42M | -54.90M | -38.48M | -25.64M | |||
| Additional Paid In Capital | 87.31M | 82.64M | 67.91M | 58.11M | 40.75M | |||
| Minority Interest | -379.14K | -257.08K | 140.00K | 30.00K | -780.00K | |||
| Common Shares | 12.71K | 7.94K | 30.00K | 30.00K | 20.00K | |||
| Treasury Stock | -8.90M | -8.90M | -9.10M | -9.10M | -9.10M | |||
| Other Shareholders' Equity | 492.32K | 64.91K | -840.00K | -1.72M | -2.60M | |||
| Shares Outstanding | 12.71M | 7.94M | 3.29M | 2.89M | 2.44M | |||
| Tangible Book Value per Share | 0.66 | 1.06 | 0.94 | 3.06 | 1.41 | |||
| Total Shareholders' Equity | 8.36M | 8.39M | 3.10M | 8.84M | 3.44M | |||
| TOTAL LIABILITIES AND EQUITY | 14.46M | 14.49M | 9.86M | 13.70M | 11.61M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | 1.30 | |||
| Current Ratio | 0.34 | 0.28 | 0.51 | 2.61 | 1.27 | |||
| Return On Assets (ROA) | -57.00% | -72.56% | -166.53% | -93.72% | -84.32% | |||
| Return On Equity (ROE) | -98.62% | -125.36% | -529.68% | -145.25% | -284.59% | |||
All data in USD , ROIC based on taxRate of 0.21